Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Show more

Location: 1901 West 47th Place, Kansas City, KS, 66205, United States | Website: https://www.cingulate.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

21.95M

52 Wk Range

$1.80 - $20.83

Previous Close

$4.81

Open

$4.87

Volume

154,634

Day Range

$4.77 - $5.25

Enterprise Value

12.84M

Cash

9.519M

Avg Qtr Burn

-3.578M

Insider Ownership

2.40%

Institutional Own.

3.22%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.